Special Issue "Marine Anti-inflammatory and Antioxidant Agents 2021"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 15 September 2021.

Special Issue Editors

Prof. Dr. Donatella Degl'Innocenti
E-Mail Website
Guest Editor
Dipartimento di Scienze Biomediche, Sperimentali e Cliniche “Mario Serio”, Università degli Studi di Firenze, viale Morgagni 50, 50134 Firenze, Italy
Interests: bioactive natural products; inflammation; oxidative stress; polyphenols; cell migration; autophagy
Special Issues and Collections in MDPI journals
Dr. Marzia Vasarri
E-Mail Website
Guest Editor
Dipartimento di Scienze Biomediche, Sperimentali e Cliniche “Mario Serio”, Università degli Studi di Firenze, viale Morgagni 50, 50134 Firenze, Italy
Interests: bioactive natural products; inflammation; oxidative stress; polyphenols; cell migration; autophagy
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammation is a normal defense process involving the innate and adaptive immune systems occurring in response to harmful stimuli, such as pathogens, damaged cells, or toxic compounds. The inflammatory cascade includes the activation of intracellular signaling pathways that regulate the levels of proinflammatory mediators in resident tissue cells and recruited inflammatory cells. In addition, inflammatory cells are known to release several ROS at the site of inflammation, leading to uncontrolled oxidative stress. On the other hand, high levels of ROS/RNS can initiate an intracellular signaling cascade that increases proinflammatory gene expression. Oxidative stress and inflammation are thus two closely related pathophysiological processes, each of which can be induced by the other.

The impact of inflammation and related oxidative stress is currently a major issue in human health. Numerous chronic diseases and disorders may be profoundly linked to the interaction between oxidative stress and inflammation. Therapeutic treatments to modulate oxidative stress and/or inflammation can preserve healthy conditions or prevent chronic disease progression.

In recent decades, the use of natural products with anti-inflammatory and antioxidant activities has become increasingly widespread. In this regard, the diversity of the chemical structures of secondary metabolites of marine origin has long been the goal of research for the development of new pharmacological products beneficial to humans.

In this Special Issue, we aim to collect in vitro and/or in vivo experimental investigations that highlight the roles of bioactive compounds of marine origin as modulators of inflammation and/or oxidative stress.

Work describing the mechanisms of action and molecular interactions of compounds isolated from marine organisms is particularly encouraged. Additionally, comprehensive review articles summarizing the knowledge on marine anti-inflammatory and/or antioxidant agents supporting human health will also be considered.

Prof. Dr. Donatella Degl'Innocenti
Dr. Marzia Vasarri
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine biomolecules
  • inflammation
  • inflammation-related disease
  • proinflammatory cytokines
  • antioxidant agents
  • oxidative stress
  • systemic oxidative stress
  • ROS
  • macrophages
  • T cells
  • neutrophils

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Article
A Comparative In Vitro Evaluation of the Anti-Inflammatory Effects of a Tisochrysis lutea Extract and Fucoxanthin
Mar. Drugs 2021, 19(6), 334; https://doi.org/10.3390/md19060334 - 11 Jun 2021
Viewed by 243
Abstract
In this study, we compared the effects of a Tisochrysis lutea (T. lutea) F&M-M36 methanolic extract with those of fucoxanthin (FX) at equivalent concentration, on lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The T. lutea F&M-M36 methanolic extract contained 4.7 mg of FX and [...] Read more.
In this study, we compared the effects of a Tisochrysis lutea (T. lutea) F&M-M36 methanolic extract with those of fucoxanthin (FX) at equivalent concentration, on lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The T. lutea F&M-M36 methanolic extract contained 4.7 mg of FX and 6.22 mg of gallic acid equivalents of phenols per gram. HPLC analysis revealed the presence of simple phenolic acid derivatives. The T. lutea F&M-M36 extract exhibited a potent and concentration-dependent inhibitory activity against COX-2 dependent PGE2 production compared to FX alone. Compared to LPS, T. lutea F&M-M36 extract and FX reduced the expression of IL-6 and of Arg1 and enhanced that of IL-10 and of HO-1; T. lutea F&M-M36 extract also significantly abated the expression of NLRP3, enhanced mir-223 expression and reduced that of mir-146b, compared to LPS (p < 0.05). These findings indicate that T. lutea F&M-M36 methanolic extract has a peculiar anti-inflammatory activity against COX-2/PGE2 and NLRP3/mir-223 that might be attributable to the known anti-inflammatory effects of simple phenolic compounds found in the extract that may synergize with FX. Our data suggest that T. lutea F&M-M36 may serve as a source of anti-inflammatory compounds to be further evaluated in in vivo models of inflammation. Full article
(This article belongs to the Special Issue Marine Anti-inflammatory and Antioxidant Agents 2021)
Show Figures

Figure 1

Review

Jump to: Research

Review
Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease
Mar. Drugs 2021, 19(4), 196; https://doi.org/10.3390/md19040196 - 30 Mar 2021
Viewed by 487
Abstract
Naturally occurring biological entities with extractable and tunable structural and functional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical advancement, traditional medicinal practices to address and manage inflammatory bowel disease [...] Read more.
Naturally occurring biological entities with extractable and tunable structural and functional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical advancement, traditional medicinal practices to address and manage inflammatory bowel disease (IBD) are inefficient and the effect of the administered therapeutic cues is limited. The reasonable immune response or invasion should also be circumvented for successful clinical translation of engineered cues as highly efficient and robust bioactive entities. In this context, research is underway worldwide, and researchers have redirected or regained their interests in valorizing the naturally occurring biological entities/resources, for example, algal biome so-called “treasure of untouched or underexploited sources”. Algal biome from the marine environment is an immense source of excellence that has also been demonstrated as a source of bioactive compounds with unique chemical, structural, and functional features. Moreover, the molecular modeling and synthesis of new drugs based on marine-derived therapeutic and biological cues can show greater efficacy and specificity for the therapeutics. Herein, an effort has been made to cover the existing literature gap on the exploitation of naturally occurring biological entities/resources to address and efficiently manage IBD. Following a brief background study, a focus was given to design characteristics, performance evaluation of engineered cues, and point-of-care IBD therapeutics of diverse bioactive compounds from the algal biome. Noteworthy potentialities of marine-derived biologically active compounds have also been spotlighted to underlying the impact role of bio-active elements with the related pathways. The current review is also focused on the applied standpoint and clinical translation of marine-derived bioactive compounds. Furthermore, a detailed overview of clinical applications and future perspectives are also given in this review. Full article
(This article belongs to the Special Issue Marine Anti-inflammatory and Antioxidant Agents 2021)
Show Figures

Figure 1

Back to TopTop